RxDoctor Payments Data

Theresa Gabriel

Nurse Practitioner · Bradenton, FLNPI 1942358353

Payments from drug & device makers

$13,806in general payments, 2019–2025

Across 539 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biohaven Pharmaceuticals, Inc.$2K
  • Abbott$2K
  • Collegium Pharmaceutical, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$908
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$8006%
  • Travel & lodging$1141%
  • Food & beverage$12,88393%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,806 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$139,273
Medicare patients
355
Services billed
1,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate98$155,471
UbrelvyUbrogepant66$118,111
RelistorMethylnaltrexone Bromide49$115,556
QuliptaAtogepant72$90,591
OzempicSemaglutide45$39,796
Aimovig AutoinjectorErenumab-Aooe40$37,968
MovantikNaloxegol Oxalate65$27,824
BotoxOnabotulinumtoxina20$26,957
ReyvowLasmiditan Succinate25$18,468
ZtlidoLidocaine24$16,982
Lidocaine121$15,478
BelbucaBuprenorphine Hcl19$15,180
HorizantGabapentin Enacarbil15$14,460
Pregabalin442$12,402
Emgality PenGalcanezumab-Gnlm18$12,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox, Linzess$2,976$246,197178 claims
PfizerNurtec Odt$908$155,47198 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,106$115,55649 claims
Lilly USA, LLCReyvow$204$18,46825 claims
Scilex Pharmaceuticals Inc.Ztlido$517$16,98224 claims
Collegium Pharmaceutical, Inc.Belbuca$1,281$15,18019 claims
Hikma Pharmaceuticals USABuprenorphine Hcl$14$3,27666 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →